Filing Flows › Health Care › BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical (BMRN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · BioMarin Pharmaceutical (BMRN) Q3 2026 earnings results →
Q3 2026 Revenue up 32% year over year to $1.0B · 12¢ of every $1 of revenue lost · operating margin -8.0%
BioMarin Pharmaceutical made $1.0B in Q3 2026 (+32% Y/Y): Net product revenues $1.0B, Royalty and other revenues $11.6M. Operating margin -8.0%, net loss $123M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0B in Q3 2026, up 32% year over year and up 4% from the previous quarter. VOXZOGO was the largest line at 24% of revenue. VIMIZIM added $0.03B year over year (up 18%), 13% of the total change. Royalty and other revenues declined 25%.
Operating costs exceeded revenue by $0.08B, an operating margin of -8.0%. Total costs grew 35% against revenue growth of 32%. The fastest-growing cost line was Other operating costs (+7887%). The quarter ended with a net loss of $0.12B, after a profit of $0.04B the previous quarter.
Operating cash flow was $0.19B (down 49% year over year). Non-cash charges added back $0.13B of depreciation and amortization and $0.05B of share-based compensation. Working capital and other items added $0.13B. Capital expenditures of $0.03B left free cash flow of $0.16B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $1.0B | +32% | -8.0% | −$123M | $188M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $990M | +20% | 11.2% | $44.8M | $168M |
| Q1 2026 | 10-Q | May 5, 2026 | $766M | +3% | 16.9% | $106M | $221M |
| Q4 2025 | 10-K | Feb 26, 2026 | $875M | +17% | -5.1% | −$46.6M | $99.6M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $776M | +4% | -6.0% | −$30.7M | $369M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $825M | +16% | 33.5% | $241M | $185M |
| Q1 2025 | 10-Q | May 2, 2025 | $745M | +15% | 30.0% | $186M | $174M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
In its own words, from its 10-K, filed Feb 26, 2026.
BioMarin Pharmaceutical against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +32% against the peers' median +10%. Operating margin: -8.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Q3 2026 | $1.0B | +32% | -8.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: BioMarin Pharmaceutical 10-Q on SEC EDGAR · CIK 1048477 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns BMRN and who is buying
More on BMRN
- How BioMarin Pharmaceutical makes money: revenue by segment
- BioMarin Pharmaceutical next earnings date and what analysts expect
- BioMarin Pharmaceutical stock forecast, price target and fair value
- Who owns BioMarin Pharmaceutical stock: holders, funds and Congress trades
- BioMarin Pharmaceutical guidance and outlook
- Is BioMarin Pharmaceutical a takeover target? LBO and rumors
- BioMarin Pharmaceutical recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- BioMarin Pharmaceutical operating margin by quarter
- BioMarin Pharmaceutical net income by quarter
- BioMarin Pharmaceutical free cash flow by quarter
- BioMarin Pharmaceutical R&D spending by quarter
- BioMarin Pharmaceutical capital expenditures by quarter
- BioMarin Pharmaceutical Net product revenues revenue by quarter
- BioMarin Pharmaceutical Royalty and other revenues revenue by quarter